Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Esplugues de Llobregat
Clinical trial register · Spain

Clinical Trials in Esplugues de Llobregat, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company12 Sanofi10 AbbVie8 Amgen5 Incyte Corporation5
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Esplugues de Llobregat

122 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
134
Esplugues de Llobregat, Madrid, Barcelona
2026-07-06
Recruiting
Bayer
Phase 3
117
Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville
2026-06-01
Not yet open
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
NCT07590648Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors
DrugsTeicoplanin·Ceftazidime·Amikacin·Ciprofloxacin
Hospital Universitari Vall d'Hebron Research Institute
Phase 4
136
Barcelona, Esplugues de Llobregat, Madrid
2026-06-01
Recruiting
Incyte Corporation
Phase 2
60
Barcelona, Esplugues de Llobregat, Madrid, Málaga, Murcia, Valencia
2026-05-20
Recruiting
Boehringer Ingelheim
Phase 2
132
Barcelona, Esplugues de Llobregat, Granada, Madrid, Valencia
2026-03-23
Recruiting
Eli Lilly and Company
Phase 3
300
Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Santander, Seville, Valencia
2026-02-05
Recruiting
Eli Lilly and Company
Phase 3
150
Barakaldo, Esplugues de Llobregat, Madrid
2026-01-12
Recruiting
Novo Nordisk A/S
Phase 3
460
Barcelona, Esplugues de Llobregat, Seville
2026-01-08
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Barcelona, Esplugues de Llobregat, Madrid, Manresa, Oviedo, Pamplona, Sabadell
2026-01-08
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
Esplugues de Llobregat
2026-01-05
Recruiting
Sanofi
Phase 3
85
Esplugues de Llobregat, Madrid, Zaragoza
2025-12-18
Recruiting
Bristol-Myers Squibb
Phase 3
366
Esplugues de Llobregat, Barcelona, Madrid, Santiago de Compostela
2025-12-03
Recruiting
Sanofi
Phase 2
37
Esplugues de Llobregat, Barcelona, Madrid
2025-12-02
Recruiting
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899Catecholaminergic Polymorphic Ventricular Tachycardia
DrugCRD-4730
Cardurion Pharmaceuticals, Inc.
Phase 2
12
Esplugues de Llobregat
2025-12-01
Recruiting
Institut de Recherches Internationales Servier
Phase 1/2
20
Esplugues de Llobregat, Madrid
2025-11-24
Recruiting
Bayer
Phase 3
111
Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-11-19
Recruiting
Incyte Corporation
Phase 3
250
Alcorcón, Badalona, Barcelona, Esplugues de Llobregat, Madrid, Zaragoza
2025-11-13
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Barcelona, Esplugues de Llobregat, Madrid
2025-10-20
Recruiting
Novadip Biosciences
Phase 3
12
Esplugues de Llobregat
2025-09-02
Recruiting
Pfizer
Phase 3
6,000
Santiago de Compostela, Esplugues de Llobregat, Pozuelo de Alarcón, Torrejón de Ardoz, Madrid, Antequera, Aravaca, Seville
2025-08-25
Recruiting
Sanofi
Phase 3
723
Santiago de Compostela, Seville, Esplugues de Llobregat, Bizkaia, Barcelona, Alcalá de Henares, Madrid, Pamplona
2025-08-06
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Barcelona, Esplugues de Llobregat, Donostia / San Sebastian, Madrid, Málaga, Murcia
2025-07-14
Active, closed
Glycomine, Inc.
Phase 2/3
50
Esplugues de Llobregat, Madrid
2025-07-09
Active, closed
Incyte Corporation
Phase 3
159
Alicante, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Málaga, Santiago de Compostela
2025-06-17
Active, closed
Incyte Corporation
Phase 3
573
Barcelona, Esplugues de Llobregat, Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Manises, Santiago de Compostela
2025-06-12
Active, closed
Incyte Corporation
Phase 3
9
Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga
2025-06-04
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Esplugues de Llobregat, Barcelona, Madrid
2025-05-26
Recruiting
CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours
NCT06986811Locally Resectable Paediatric Tumours
DrugCEB-01
CEBIOTEX
Phase 2
60
Esplugues de Llobregat
2025-05-06
Recruiting
Bristol-Myers Squibb
Phase 3
194
Esplugues de Llobregat, Vigo, Seville, Valencia, Zaragoza
2025-04-08
Recruiting
UCB Biopharma SRL
Phase 3
40
Esplugues de Llobregat, Madrid, Valencia
2025-03-11
By invitation
Longboard Pharmaceuticals
Phase 3
324
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia
2025-02-12
Active, closed
PPM Services S.A.
Phase 3
400
Alcorcón, Barcelona, Esplugues de Llobregat, Granada, Madrid, Málaga, Seville, Valencia
2024-12-05
Recruiting
Takeda
Phase 3
30
Esplugues de Llobregat, Valencia
2024-11-19
Active, closed
Sanofi
Observational
143
Santiago de Compostela, Esplugues de Llobregat, Oviedo, Seville, Alicante, Barcelona, Madrid, Málaga
2024-11-14
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia
2024-11-11
By invitation
Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy
NCT06696456Otoferlin Gene-mediated Hearing Loss
Akouos, Inc.
Observational
30
Esplugues de Llobregat
2024-11-11
Active, closed
Eli Lilly and Company
Phase 2
45
Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Seville, Valencia
2024-10-25
Active, closed
Amgen
Phase 3
19
Barcelona, Esplugues de Llobregat, Madrid
2024-10-22
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Esplugues de Llobregat, Madrid
2024-09-30
Active, closed
Longboard Pharmaceuticals
Phase 3
96
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga
2024-09-25
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
Esplugues de Llobregat, Oviedo, Seville, Madrid
2024-08-21
Recruiting
AbbVie
Phase 3
675
Esplugues de Llobregat, Madrid, Valencia, Zaragoza
2024-08-19
Recruiting
AbbVie
Phase 3
110
Ferrol, Esplugues de Llobregat, Málaga, Seville, Zaragoza
2024-08-08
Recruiting
AbbVie
Phase 3
40
Esplugues de Llobregat, Valencia
2024-07-08
Active, closed
UCB Biopharma SRL
Phase 3
176
Alicante, Esplugues de Llobregat, Granada
2024-06-25
Active, closed
Sanofi
Phase 3
1,541
Esplugues de Llobregat, Bilbao, Las Palmas de Gran Canaria, Pamplona, Vigo, Seville, Burjassot - Valencia, Alicante
2024-05-08
Active, closed
Amgen
Phase 3
111
Barakaldo, Barcelona, Esplugues de Llobregat, Getafe, Valencia, Madrid
2024-04-22
Recruiting
AstraZeneca
Phase 3
100
Esplugues de Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia
2024-03-14
Recruiting
argenx
Observational
100
Esplugues de Llobregat, Madrid, Valencia
2024-02-13
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
100
Esplugues de Llobregat, Madrid
2024-01-16
By invitation
Sanofi
Phase 3
90
Santiago de Compostela, Barcelona, Esplugues de Llobregat, Sabadell, Jerez de la Frontera, Madrid, Valencia
2024-01-03
Active, closed
HENKA: Growing in Emotional Well-being
NCT07796867Mental Health, Resilience, Psychological, Emotional Well-being
Fundació Sant Joan de Déu
Not applicable
1,084
Esplugues de Llobregat
2024-01-01
Active, closed
Sanofi
Phase 2
197
Barcelona, Esplugues de Llobregat, Oviedo, Seville, Málaga, Valencia, Vitoria-Gasteiz
2023-12-11
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
L'Hospitalet de Llobregat, Barcelona, Esplugues de Llobregat, Madrid
2023-11-20
Active, closed
AbbVie
Phase 3
122
Ferrol, Esplugues de Llobregat, Barcelona, Málaga
2023-11-06
Active, closed
Janssen Research & Development, LLC
Phase 3
311
Badalona, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Seville, Valencia
2023-10-12
Recruiting
AbbVie
Phase 3
90
Esplugues de Llobregat, Valencia
2023-10-02
By invitation
Sarepta Therapeutics, Inc.
Phase 3
400
Esplugues de Llobregat, Valencia
2023-09-27
Recruiting
Hoffmann-La Roche
Phase 1/2
60
Esplugues de Llobregat, Madrid, Málaga
2023-09-21
Recruiting
ModernaTX, Inc.
Observational
60
Esplugues de Llobregat, Santander, Barakaldo, Madrid, Seville, Valencia
2023-06-16
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
148
Esplugues de Llobregat, Valencia
2023-05-31
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
Esplugues de Llobregat, Barcelona, A Coruña, Madrid, Seville
2023-05-31
Recruiting
Pfizer
Phase 2
100
Santiago de Compostela, Barcelona, Esplugues de Llobregat, Madrid, El Palmar, Seville, Valencia
2023-05-17
Recruiting
Pfizer
Phase 2
48
Badalona, Esplugues de Llobregat, Madrid, Barcelona
2023-04-18
Active, closed
AstraZeneca
Phase 3
94
Badalona, Barcelona, Benalmádena, Esplugues de Llobregat
2023-04-05
By invitation
Eli Lilly and Company
Phase 3
333
Esplugues de Llobregat, Las, Madrid, Pozuelo de Alarcón, Pamplona, Pontevedra, Manises
2023-03-09
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
20
Esplugues de Llobregat, Sabadell, Barcelona, Seville
2023-01-23
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Valencia
2023-01-23
Recruiting
Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction
NCT05038462Fetal Growth Retardation, Intrauterine Growth Restriction
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Not applicable
304
Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat
2023-01-18
Recruiting
Bayer
Phase 3
100
Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville
2022-11-08
Active, closed
Eli Lilly and Company
Phase 3
377
Esplugues de Llobregat, Las, Madrid, Pamplona
2022-10-18
Active, closed
Genmab
Phase 1
17
Barcelona, Esplugues de Llobregat, Madrid
2022-10-04
Active, closed
Eli Lilly and Company
Phase 2
46
Barcelona, Esplugues de Llobregat, Madrid, Seville, Valencia
2022-09-20
Recruiting
Giselle Sholler
Phase 2
93
Esplugues de Llobregat
2022-09-14
Active, closed
Novo Nordisk A/S
Phase 3
412
Santiago de Compostela, Boadilla del Monte, Esplugues de Llobregat
2022-08-10
Recruiting
Otoferlin Gene-mediated Hearing Loss Natural History Study
NCT05572073Sensorineural Hearing Loss, Bilateral
Akouos, Inc.
Observational
150
Esplugues de Llobregat
2022-07-14
Active, closed
Biohaven Pharmaceuticals, Inc.
Phase 3
269
Donostia / San Sebastian, Esplugues de Llobregat, Málaga, Valencia
2022-07-06
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2/3
12
Esplugues de Llobregat
2022-06-23
Recruiting
Bristol-Myers Squibb
Phase 2/3
120
Badalona, Esplugues de Llobregat, Madrid
2022-05-30
Recruiting
SK Life Science, Inc.
Phase 3
252
Esplugues de Llobregat, Madrid
2022-04-28
Active, closed
Bayer
Phase 3
219
Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville
2022-03-28
Recruiting
Amgen
Phase 3
60
San Cristóbal de La Laguna, Barcelona, Esplugues de Llobregat, Valencia, Madrid
2022-03-17
Recruiting
Takeda
Phase 3
120
Esplugues de Llobregat, Sagunto, Madrid, Málaga, Seville
2022-02-10
Recruiting
argenx
Phase 2/3
12
Esplugues de Llobregat, Valencia
2021-10-26
Recruiting
Amgen
Phase 3
60
Seville, Barcelona, Esplugues de Llobregat, Valencia, Madrid
2021-09-09
Active, closed
Sanofi
Phase 3
17
Esplugues de Llobregat
2021-09-01
Active, closed
AbbVie
Phase 3
132
Esplugues de Llobregat, Madrid, Pontevedra
2021-07-24
Active, closed
Sanofi
Observational
16
Esplugues de Llobregat
2021-06-10
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Córdoba, Esplugues de Llobregat, Sabadell, Valencia
2021-05-26
Recruiting
Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics
NCT05761080Laparoscopic Appendectomy, Complicated Appendicitis, Periappendicular Abscess
DrugMaximum
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase 4
772
Barcelona, Córdoba, Lleida, Madrid, Seville, Badalona, Esplugues de Llobregat, Girona
2021-04-22
Recruiting
ModernaTX, Inc.
Phase 1/2
77
Esplugues de Llobregat, Barakaldo, Madrid, Seville
2021-04-15
Active, closed
Eli Lilly and Company
Phase 3
101
Esplugues de Llobregat, Madrid, Málaga, Seville, Valencia
2021-04-13
Recruiting
Bristol-Myers Squibb
Phase 3
153
Alicante, Barakaldo, Esplugues de Llobregat, Las Palmas de GC, Madrid
2021-03-23
Recruiting
Genethon
Phase 2/3
77
Esplugues de Llobregat, Valencia
2021-03-01
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Esplugues de Llobregat, Madrid
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
55
Esplugues de Llobregat, Madrid, Seville
2021-02-04
Active, closed
Amgen
Phase 1/2
181
Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona
2021-01-04
Recruiting
Integrative Diagnosis for SCD and Other RADs
NCT07206095Sickle Cell Disease, Thalassaemia, Congenital Dyserythropoietic Anemia (CDA), Enzyme Disorder; Anemia
Hospital Universitari Vall d'Hebron Research Institute
Observational
200
Barcelona, Esplugues de Llobregat, Granollers, Mataró, Sabadell, Terrassa, Lleida
2020-11-13
Active, closed
Pfizer
Phase 3
114
Esplugues de Llobregat, Barcelona, Valencia
2020-11-05
Recruiting
Mats Heyman
Phase 3
6,430
Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Palma de Mallorca, Seville, Valencia, Zaragoza
2020-07-13
Recruiting
Fundació Sant Joan de Déu
Observational
1,000
Esplugues de Llobregat
2020-05-05
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Seville, Valencia
2020-03-12
Active, closed
Eli Lilly and Company
Phase 3
58
Esplugues de Llobregat, Madrid, Seville, Valencia
2020-02-12
Recruiting
Eli Lilly and Company
Phase 2
105
Barcelona, Esplugues de Llobregat, Madrid, San Cristóbal de La Laguna, Seville, Valencia
2020-01-22
Active, closed
Actelion
Phase 3
138
A Coruña, Barcelona, Esplugues de Llobregat, Madrid, Seville
2020-01-16
Recruiting
Natural History of Duchenne Muscular Dystrophy
NCT03882827Duchenne Muscular Dystrophy
Genethon
Observational
220
Esplugues de Llobregat, Valencia
2019-12-19
Active, closed
Biogen
Phase 3
152
Esplugues de Llobregat, El Palmar, Córdoba, Madrid
2019-10-18
Active, closed
Eli Lilly and Company
Phase 3
30
Esplugues de Llobregat, Madrid, Valencia
2019-10-16
Recruiting
University Hospital Muenster
Phase 3
683
Alicante, Almería, Badajoz, Barakaldo, Barcelona, Donostia / San Sebastian, Esplugues de Llobregat, Granada
2019-08-23
Active, closed
AbbVie
Phase 1
124
Esplugues de Llobregat, Madrid, Valencia
2019-06-24
Recruiting
Eli Lilly and Company
Phase 3
190
Esplugues de Llobregat, Madrid, Seville, Valencia
2019-04-05
Recruiting
AstraZeneca
Phase 3
140
Esplugues de Llobregat, Madrid
2019-04-02
Recruiting
Sanofi
Phase 2
51
Esplugues de Llobregat, Barcelona, Madrid, Málaga, Valencia
2018-08-09
Recruiting
Celgene
Phase 2/3
1,541
Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Málaga, Pamplona, Salamanca, Santander
2018-07-19
Recruiting
Fundació Sant Joan de Déu
Observational
90
Esplugues de Llobregat, Barcelona
2018-06-01
Active, closed
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc.
Observational
500
Badalona, Esplugues de Llobregat, Barcelona, Madrid, Tortosa
2018-04-23
Recruiting
Fundació Institut Germans Trias i Pujol
Observational
200
Badalona, Esplugues de Llobregat, Barcelona
2018-04-19
Recruiting
Fundació Sant Joan de Déu
Not applicable
30
Esplugues de Llobregat
2018-01-10
Recruiting
Italfarmaco
Phase 2/3
206
Esplugues de Llobregat, Barcelona, Seville, Valencia
2017-10-24
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Barakaldo, Barcelona, Cartagena, El Palmar, Esplugues de Llobregat, Las Palmas de Gran Canaria, Madrid, Oviedo
2017-09-12
Active, closed
Janssen Sciences Ireland UC
Phase 2
48
Esplugues de Llobregat
2015-07-06
Active, closed
AbbVie
Observational
1,446
A Coruña, Ferrol, Santiago de Compostela, Palma de Mallorca, Badalona, Esplugues de Llobregat, Sabadell, Leganés
2014-08-28
Rows per page Showing 1–122 of 122
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/esplugues-de-llobregat

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 122 of those studies with a site in Esplugues de Llobregat.

How many clinical trials are recruiting in Esplugues de Llobregat?

72 of the 122 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 43 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Esplugues de Llobregat), 122 studies
PhaseStudiesRecruitingShare
Phase 3673554.9%
Phase 2161013.1%
Observational151012.3%
Phase 2/3977.4%
Phase 1/2765.7%
Not applicable322.5%
Phase 1312.5%
Phase 4211.6%

Most active sponsors

Lead sponsors with the most studies (Esplugues de Llobregat)
Lead sponsorStudiesRecruiting
Eli Lilly and Company125
Sanofi104
AbbVie84
Amgen52
Incyte Corporation52
Bayer43
Bristol-Myers Squibb44
Fundació Sant Joan de Déu43
Pfizer43
argenx33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.